当前位置：易推广 > 上海陶术生物科技有限公司 > 产品展示
企业档案
会员类型：会员
已获得易推广信誉 等级评定
(0 -40)基础信誉积累，可浏览访问
(41-90)良好信誉积累，可接洽商谈
(91+ )优质信誉积累，可持续信赖
易推广会员：5年
工商认证 【已认证】
最后认证时间：
注册号： 【已认证】
法人代表： 【已认证】
企业类型：生产商 【已认证】
注册资金：人民币万 【已认证】
产品数：86101
参观次数：3546225
自主品牌
已选条件
-
T6222PFI-1；化合物PFI1PF-6405761|||PFI 1|||PFI1；PF-6405761|||PFI 1|||PFI1
PFI-1 (PF-6405761), a specific BET (bromodomain-containing protein) inhibitor for BRD4, is with the IC50 of 0.22 μM in a cell-free assay.
价 格：￥电议型 号：T6222产 地：中国大陆
-
T6143PI-103；化合物PI103PI103|||PI 103；PI103|||PI 103
PI-103 is a potent, cell-permeable, ATP-competitive inhibitor of PI3K family members (IC50s: 2/3/3/15/30/23 nM for p110α/β/δ/γ, mTOR, and DNA-PK).
价 格：￥电议型 号：T6143产 地：中国大陆
-
T6108Ki16425；化合物Ki16425Debio 0719；Debio 0719
Ki16425 (Debio 0719) is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively.
价 格：￥电议型 号：T6108产 地：中国大陆
-
T61016EMI1；化合物EMI1EMI1
EMI1 is an inhibitor of EGFR ex19del/T790M/C797S and EGFR L858R/T790M/C797S. EMI1 has research value in the research of mutant EGFR-associated, drug-resistant non-small-cell lung cancer (NSCLC).
价 格：￥电议型 号：T61016产 地：中国大陆
-
T60163Lurtotecan；勒托替康GI147211|||OSI-211；GI147211|||OSI-211
Lurtotecan (GI147211) is a semisynthetic Camptothecin analog. Lurtotecan is a topoisomerase I inhibitor with anticancer effects.
价 格：￥电议型 号：T60163产 地：中国大陆
-
T6009TAPI1化合物TAPI1TAPI 1|||TAPI|||TAPI-1
TAPI1 (TAPI) , an ADAM17/TACE inhibitor, inhibits shedding of cytokine receptors.
价 格：￥电议型 号：T6009产 地：中国大陆
-
T5210BAI1；化合物BAI1BAI1
BAI1 (Bax channel blocker) is a potent inhibitor of Bax-mediated mitochondrial cytochrome C release (IC50: 0.52 μM).
价 格：￥电议型 号：T5210产 地：中国大陆
-
T51329-dihydro-13-acetylbaccatin III；13-乙酰基-9-羟基巴卡丁 III13-Acetyl-9-dihydrobaccatin III|||9-DHAB III；13-乙酰
9-dihydro-13-acetylbaccatin III (9-DHAB III)is an apoptosis inducer. It shows cytotoxicity against the MCF7 cell line and drug-resistant cell line MCF7-ADR.
价 格：￥电议型 号：T5132产 地：中国大陆
-
T41204TAT-Gap19(I130A)；TAT-Gap19(I130A)TAT-Gap19(I130A)；TAT-Gap19(I130A)
TAT-Gap19(I130A) is a control peptide for TAT-Gap19, a Cx43 hemichannel blocker. TAT-Gap19(I130A) consists of TAT-GAP19 with a I130A amino acid residue change at a key residue for GAP19 activity. In C6 glioma cells expression Cx43, TAT-GAP19(1130A) does not inhibit [Ca2+]i-triggered ATP release at 200 μM. TAT-Gap19(I130A) is cell permeable.
价 格：￥电议型 号：T41204产 地：中国大陆
-
T3988TOFA；化合物TOFAMDL14514|||RMI14514；MDL14514|||RMI14514
TOFA (MDL14514) is an allosteric inhibitor of acetyl-CoA carboxylase-α (ACCA).
价 格：￥电议型 号：T3988产 地：中国大陆
-
-
T38392JAMI1001A；JAMI1001AJAMI1001A
JAMI1001A is a positive allosteric modulator of the AMPA receptor, effectively modulating the deactivation and desensitization of both flip and flop receptor isoforms.
价 格：￥电议型 号：T38392产 地：中国大陆
-
T38377ADTL-EI1712；ADTL-EI1712ADTL-EI1712；ADTL-EI1712
ADTL-EI1712 is a dual inhibitor of ERK1 and ERK5 (IC50s = 40.43 and 64.5 nM, respectively).1It reduces ERK1 and ERK5 activity by 93.5% and 89.4%, respectively, but also inhibits ERK2 activity by 92.7%, in a panel of 100 kinases at 1 μM. ADTL-EI1712 inhibits proliferation of HL-60 and MKN74, but not HeLa, cancer cells (IC50s = 1.26, 2.55, and >50 μM, respectively). It reduces tumor growth and intratumor phosphorylation of ERK1/2 and ERK5 in an MKN74 mouse xenograft model when administered at a do
价 格：￥电议型 号：T38377产 地：中国大陆
-
T36643PKI-166 hydrochloridePKI 166 hydrochloridePKI166 hydrochloride|||PKI 166 hydrochloride
Potent EGFR-kinase inhibitor (IC50 = 0.7 nM). Displays >3000-fold selectivity against a panel of serine/threonine kinases. Reduces metastasis and angiogenesis in a mouse model of pancreatic cancer. Antihypertensive and orally bioavailable.
价 格：￥电议型 号：T36643产 地：中国大陆
-
T362396β-Prostaglandin I1；6β-Prostaglandin I16β-Prostaglandin I1；6β-Prostaglandin I1
6β-PGI1 is a stable PGI2 analog resistant to hydrolysis in aqueous solutions. 6β-PGI1 has a much longer half-life than PGI2, but a greatly reduced molar potency for receptor mediated function. 6β-PGI1 has a Kact for adenylate cyclase in NCB-20 cells of 4.2 μM compared with 18 nM for PGI2. The potency for vasodilation and inhibition of platelet aggregation is about 1% of PGI2.
价 格：￥电议型 号：T36239产 地：中国大陆
-
T362386α-Prostaglandin I1；6α-Prostaglandin I16α-Prostaglandin I1；6α-Prostaglandin I1
6α-Prostaglandin I1 (6α-PGI1) is a stable Prostaglandin I2 (PGI2) analog resistant to hydrolysis in aqueous solutions. 6α-PGI1 promotes cyclic AMP accumulation in human thyroid slices and cells in a concentration dependent manner. However, it is about 10-fold less potent than the β-isomer and 100-fold less potent than PGI2 in eliciting the response. 6α-PGI1 exhibits an IC50 of 350 ng/ml for inhibition of ADP-induced platelet aggregation, which is nearly 900-fold higher than that observed for PGI
价 格：￥电议型 号：T36238产 地：中国大陆
-
T3561CPI1189；化合物CPI1189CPI-1189|||REN-1189|||CPI 1189；CPI-1189|||REN-1189|||CPI 1189
CPI1189 (REN-1189) is a TNF-a release inhibitor potentially for the treatment of sciatica and postherpetic neuralgia.
价 格：￥电议型 号：T3561产 地：中国大陆
-
T35299Zenarestat；化合物 T35299CI1014|||FR74366|||FK-366|||CI-1014|||FR 74366|||FR-74366；CI1014|||FR74366|||FK
Zenarestat (CI-1014, FK-366, FR-74366) is an aldose reductase inhibitor being studied as a treatment for diabetic neuropathy and cataracts.
价 格：￥电议型 号：T35299产 地：中国大陆
-
T35000Uproleselan sodium；化合物 T35000GMI 1271|||GMI1271|||GMI-1271；GMI 1271|||GMI1271|||GMI-1271
Uproleselan sodium (GGI-1271) is a small molecule E-selector antagonist originally targeted at AML as an adjuvant to standard chemotherapy for hematological malignancies.
价 格：￥电议型 号：T35000产 地：中国大陆
-
T3476JI-101；化合物JI101CGI-1842|||JI 101；CGI-1842|||JI 101
JI-101 (CGI-1842) is an oral multi-kinase inhibitor that targets vascular endothelial growth factor receptor type 2 (VEGFR-2), platelet derived growth factor receptor β (PDGFR-β), and ephrin type-B receptor 4 (EphB4).
价 格：￥电议型 号：T3476产 地：中国大陆
